HALO

Nasdaq

HALOZYME THERAPEUTICS, INC.

Latest disclosureOctober 2, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 61 sales

Price by TradingView

Insider transactions 122

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. Sales: $9.05M by 2 insiders.

Showing the first 6 of 20 trades on this page.

Sale disclosed

Matthew L. Posard

Director

Common Stock

Reported value: $78.23K
Reported price: $107.168 / share

Sale disclosed

Matthew L. Posard

Director

Common Stock

Reported value: $357.9K
Reported price: $108.454 / share

Sale disclosed

Matthew L. Posard

Director

Common Stock

Reported value: $120.53K
Reported price: $109.569 / share

Sale disclosed

Matthew L. Posard

Director

Common Stock

Reported value: $11K
Reported price: $110.04 / share

Sale disclosed

Matthew L. Posard

Director

Common Stock

Reported value: $329.01K
Reported price: $106.132 / share

Sale disclosed

Matthew L. Posard

Director

Common Stock

Reported value: $320.48K
Reported price: $106.828 / share

Sale disclosed

Matthew L. Posard

Director

Common Stock

Reported value: $961.12K
Reported price: $108.04 / share

Sale disclosed

Matthew L. Posard

Director

Common Stock

Reported value: $435.96K
Reported price: $108.991 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $1.43M
Reported price: $107.222 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $711.19K
Reported price: $107.821 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $10.87K
Reported price: $108.67 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $1.56M
Reported price: $107.012 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $582.23K
Reported price: $107.581 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $1.66M
Reported price: $107.154 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $484.83K
Reported price: $107.548 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $89.06K
Reported price: $98.958 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $50.23K
Reported price: $100.457 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $213.71K
Reported price: $101.766 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $922.98K
Reported price: $102.553 / share

Sale disclosed

Helen Torley

PRESIDENT AND CEO

Common Stock

Reported value: $776.12K
Reported price: $103.482 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
Director	Common StockSale10b5-14 trades	5,230avg $108.54 / share	$567.66K	Oct 1Filed Oct 2 · 1d later	4 filings 730 @ $107.17 · $78.23KSEC filing 3,300 @ $108.45 · $357.9KSEC filing 1,100 @ $109.57 · $120.53KSEC filing 100 @ $110.04 · $11KSEC filing
Director	Common StockSale10b5-14 trades	18,996avg $107.74 / share	$2.05M	Sep 16Filed Sep 17 · 1d later	4 filings 3,100 @ $106.13 · $329.01KSEC filing 3,000 @ $106.83 · $320.48KSEC filing 8,896 @ $108.04 · $961.12KSEC filing 4,000 @ $108.99 · $435.96KSEC filing
PRESIDENT AND CEO	Common StockSale10b5-13 trades	20,000avg $107.43 / share	$2.15M	Sep 9Filed Sep 11 · 2d later	3 filings 13,304 @ $107.22 · $1.43MSEC filing 6,596 @ $107.82 · $711.19KSEC filing 100 @ $108.67 · $10.87KSEC filing
PRESIDENT AND CEO	Common StockSale10b5-12 trades	20,000avg $107.17 / share	$2.14M	Sep 10Filed Sep 11 · 1d later	2 filings 14,588 @ $107.01 · $1.56MSEC filing 5,412 @ $107.58 · $582.23KSEC filing
PRESIDENT AND CEO	Common StockSale10b5-12 trades	20,000avg $107.24 / share	$2.14M	Sep 11Filed Sep 11 · 0d later	2 filings 15,492 @ $107.15 · $1.66MSEC filing 4,508 @ $107.55 · $484.83KSEC filing
PRESIDENT AND CEO	Common StockSale10b5-15 trades	20,000avg $102.60 / share	$2.05M	Aug 17Filed Aug 19 · 2d later	5 filings 900 @ $98.96 · $89.06KSEC filing 500 @ $100.46 · $50.23KSEC filing 2,100 @ $101.77 · $213.71KSEC filing 9,000 @ $102.55 · $922.98KSEC filing 7,500 @ $103.48 · $776.12KSEC filing

Showing the latest 20 of 61 trades. Show all 61 trades

Congress transactions 1

All Congress filings

Purchase disclosed

Halozyme Therapeutics, Inc. - Common Stock (HALO) · Stock

The filing reports a purchase for the member.

Gilbert CisnerosReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 9, 2026

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001159036
Latest public acceptance: Oct 2, 2026, 08:43 PM UTC
Score calculated: Oct 8, 2026, 03:53 PM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

Director

Common StockSale10b5-14 trades

5,230avg $108.54 / share

$567.66K

Oct 1Filed Oct 2 · 1d later

4 filings

730 @ $107.17 · $78.23KSEC filing
3,300 @ $108.45 · $357.9KSEC filing
1,100 @ $109.57 · $120.53KSEC filing
100 @ $110.04 · $11KSEC filing

Director

Common StockSale10b5-14 trades

18,996avg $107.74 / share

$2.05M

Sep 16Filed Sep 17 · 1d later

4 filings

3,100 @ $106.13 · $329.01KSEC filing
3,000 @ $106.83 · $320.48KSEC filing
8,896 @ $108.04 · $961.12KSEC filing
4,000 @ $108.99 · $435.96KSEC filing

PRESIDENT AND CEO

Common StockSale10b5-13 trades

20,000avg $107.43 / share

$2.15M

Sep 9Filed Sep 11 · 2d later

3 filings

13,304 @ $107.22 · $1.43MSEC filing
6,596 @ $107.82 · $711.19KSEC filing
100 @ $108.67 · $10.87KSEC filing

PRESIDENT AND CEO

Common StockSale10b5-12 trades

20,000avg $107.17 / share

$2.14M

Sep 10Filed Sep 11 · 1d later

2 filings

14,588 @ $107.01 · $1.56MSEC filing
5,412 @ $107.58 · $582.23KSEC filing

PRESIDENT AND CEO

Common StockSale10b5-12 trades

20,000avg $107.24 / share

$2.14M

Sep 11Filed Sep 11 · 0d later

2 filings

15,492 @ $107.15 · $1.66MSEC filing
4,508 @ $107.55 · $484.83KSEC filing

PRESIDENT AND CEO

Common StockSale10b5-15 trades

20,000avg $102.60 / share

$2.05M

Aug 17Filed Aug 19 · 2d later

5 filings

900 @ $98.96 · $89.06KSEC filing
500 @ $100.46 · $50.23KSEC filing
2,100 @ $101.77 · $213.71KSEC filing
9,000 @ $102.55 · $922.98KSEC filing
7,500 @ $103.48 · $776.12KSEC filing

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001159036
Latest public acceptance: Oct 2, 2026, 08:43 PM UTC
Score calculated: Oct 8, 2026, 03:53 PM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.